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accepted July 30,bstructive thrombosed prosthetic heart valve (OTPHV) is a serious complication of heart valve replacement. There
are no generally accepted criteria for management of these patients. Therefore, in September 2012, a literature
survey of studies published after 1995 was performed to analyze the data regarding clinical outcomes of patients
with OTPHV treated with thrombolytic agents and with surgery since 1996. The search yielded appropriate and
relevant studies, which included 17 studies comprising 756 patients who had received thrombolytic therapy and
13 studies comprising 662 patients who had received surgery. The data on these 2 groups was analyzed in detail
relating to frequency of use of the diagnostic studies, baseline patient data, and on the rate of complete success,
outcomes, and complications of the therapy they had received, and the limitations of the studies. We have then
developed a strategy for therapy of OTPHV. (J Am Coll Cardiol 2013;62:1731–6) ª 2013 by the American College
of Cardiology FoundationObstructive thrombosed prosthetic heart valve (OTPHV) is an
uncommon complication of prosthetic heart valve (PHV).
However, when it occurs, it is associated with signiﬁcant
mortality and morbidity. The American College of Cardi-
ology/American Heart Association and the American College
of Chest Physicians guidelines do not have any Class I or
Class III recommendations for treatment of OTPHV (1,2).
The 2006 American College of Cardiology/American Heart
Association guidelines provide Class II recommendations in
which the level of evidence was “C” in all 3 of the IIa
recommendations and in 2 of the 4 IIb recommendations. The
recent 2012 European Society of Cardiology and the Euro-
pean Association for Cardio-Thoracic Surgery guidelines gave
a Class I recommendation for surgery in “critically” ill patients
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2013.Evidence was C (3). “Critically” was not deﬁned. However,
these guidelines have now made an essential and important
distinction between obstructive thrombus and nonobstructive
thrombus, which needs to be emphasized (3). The European
Society of Cardiology/European Association of Cardio-
Thoracic Surgery guidelines recommend, if surgery is not
immediately available for OTPHV, that the patient should
receive thrombolytic therapy. All the guidelines cite a very
small number of references to single studies for the manage-
ment of these patients. These recommendations indicated to
us that a study of clinical outcomes of therapy from a
comprehensive analysis of data of all published studies would
be useful, valuable, and would also be of help for inclusion in
the next revised guidelines.
There are 2 forms of therapy, thrombolytic therapy and
surgical replacement of the OTPHV. Our goal was to
determine the clinical outcomes of the use of these 2 forms
of therapy. Outcome of treatment has been generally cate-
gorized into “complete success,” “partial success,” or “inef-
fective.” Complete success is complete resolution of the
thrombus and the obstruction. The remainder are consid-
ered a “failure” and include partial success, which is
incomplete resolution of the thrombus and/or obstruction,
and ineffective, which is no discernible change in the
thrombus and the obstruction. For use of thrombolytic
agents, 2 reviews were published in the 1990s (4,5), which
included data up to 1995. There are no randomized trials
except for 1 (6) in 2009 that compared an accelerated dose
versus a conventional dose of streptokinase for the treat-
ment of OTPHV and showed no differences in outcomes.
Abbreviations
and Acronyms
CVA = cardiovascular
accident(s)
NYHA = New York Heart
Association
OTPHV = obstructive
thrombosed prosthetic
heart valve
PHV = prosthetic heart
valve
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiography
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1732Therefore, in September 2012,
we undertook a literature survey
of studies published after 1995
to analyze the data that would
be focused on and would criti-
cally evaluate clinical outcomes
of patients with OTPHV treated
with thrombolytic agents and with
surgery since 1996.Literature Survey
In September 2012, encompass-
ing a 17-year time period, a
PubMed literature survey was
performed using the terms “pros-Table 1
Pannus and/or Thrombus in OTPHV Diagnosed
at Surgery
First Author (Ref. #) Thrombus Pannus Thrombus þ Pannusthetic heart valve” and “thrombosis” for all English language
articles published from 1996 to September 2012. The
search returned 1,667 articles, of which 65 were identiﬁed
that were related to PHV thrombus. From the 65 articles,
topics unrelated to PHV thrombosis were excluded. Also
excluded were articles that related to PHV thrombus, trans-
catheter aortic valves, pregnancy, case reports, studies with
<5 patients, editorials, and reviews. When there were
multiple studies from the same medical center(s) and similar
authors, only the most recent study was included. A few
studies had compared data on thrombolytic agents and
surgery; however, in these studies: 1) the therapies were not
given as part of randomized trials or in a systematic pre-
determined protocol; 2) the baseline characteristics of the
patients in the 2 groups were not adequately described and/
or were not similar; and 3) the number of patients in each
group were too small and/or were not comparable. Therefore,
the ﬁndings in the 2 groups were included with the rest of
the studies on thrombolytic agents and on surgery, respec-
tively. To ensure that no studies were missed, the cited
references in the relevant studies were also reviewed; some of
the articles were ﬁnally retrieved through interlibrary loans
by the University of Southern California Medical School
Library. The search eventually yielded 17 studies, comprising
756 patients (6–22) (Online Table A), which were related to
thrombolytic agents in OTPHV and 13 studies, comprising
662 patients (7,11,16,17,21–29) (Online Table B), which
were related to surgery in OTPHV.Aoyagi et al. (7) 16 4
Lengyel et al. (11) 11 8 1
Durrleman et al. (16) 13 5 20
Renzulli et al. (17) 78 93 42
Keeulers et al. (22) 10 9
Rizzoli et al. (23) 25 33 13
Bollag et al. (24) 11 5
Ozkokeli et al. (25) 25 5
Lafci et al. (26) 6 5 7
Toker et al. (27) 18 45
Total (n ¼ 518) 213 (41%) 198 (38%) 107 (21%)
Values n or n (%).
OTPHV ¼ obstructive thrombosed prosthetic heart valve.Findings
Diagnosis. The diagnosis of OTPHV was based on clinical
assessment and imaging modalities including ﬂuoroscopy
and echocardiography. Of the available data in 22 studies
(6–14,16–22,24–29), 59% of the studies utilized ﬂuo-
roscopy, 86% of the studies utilized transthoracic echo-
cardiography (TTE), and 77% of the studies utilized
transesophageal echocardiography (TEE). Nine percent of
the studies utilized only TTE, and 9% utilized only TEE.
Forty-one percent utilized 2 imaging modalities (56%utilized both TTE and TEE, and 44% used a combination
of ﬂuoroscopy and echocardiography), and 41% utilized all
3 imaging modalities.
Pannus/thrombus. Ten studies presented data regarding
ﬁndings of thrombus and/or pannus at the time of surgery
for a total of 518 patients (7,11,16,17,22–27) (Table 1); 41%
had thrombus only, 38% had pannus only, and 21% had
both thrombus and pannus. Only 1 study (8) evaluated
whether patients had pannus and/or thrombus at echocar-
diography in 87 patients; 24% had thrombus only, 31% had
pannus alone, and 45% had both thrombus and pannus.
Thus, pannus was present in 59% to 76% of patients.
Previous anticoagulation. Eighteen studies provided infor-
mation regarding anticoagulation status of patients at time of
diagnosis of OTPHV (7–15,17,20–22,24–28). Of 1,005
patients, 61% had stated anticoagulation levels as adequate in
the cited studies, and 39% had stated anticoagulation levels as
inadequate in the cited studies (Table 2).
Right-sided OTPHV. ISOLATED THROMBOSIS OF THE
TRICUSPID VALVE. Nine studies, comprising 48 patients
(7,9,12,14,18,20–22,29), reported clinical outcomes for
isolated thrombosed tricuspid valve. Of 43 who had received
thrombolysis, 42 had a mechanical valve and 1 had a bio-
prosthesis. Complete success was achieved in 38 (88%)
patients, partial success was achieved in 1 patient, and was
ineffective in 4 patients. These 4 patients also needed sur-
gical tricuspid valve replacement of the OTPHV. There
were 4 additional studies (13,23,28,29) for a total of 8 pa-
tients with isolated tricuspid OTPHV, for which outcome of
therapy was not stated.
Left-sided OTPHV. LEFT-SIDED OTPHV TREATED WITH
THROMBOLYSIS. Seventeen studies (6–22) presented char-
acteristics and clinical outcomes of 756 patients who
received thrombolytic agents for treatment of 801 episodes
of OTPHV (Online Table A). The ﬁndings are summarized
in Table 3. The majority of the patients were female (59%);
the patients’ ages ranged from 32 to 61 years, and only
3 patients had received a bioprosthetic PHV. Of the data
that were available in 665 patients, 35% presented in
Table 3
Summary of Pooled Data of Thrombolysis in
756 Patients for 801 Episodes of Left Heart OTPHV
Mean age, yrs* 32–61
Sexy
Female 410 (59%)
Male 286 (41%)
Location of valvezx
Mitral 481 (68%)
Aortic 151 (21%)
NYHA functional class
I/IIjj 235 (35%)
III/IVjj 430 (65%)
Recurrence 106 (13%)
CVA/emboli 111 (14%)
Complete success 558 (70%)
Failures{ 243 (30%)
Partial success 85 (35%)
Subsequent surgery 38
No follow-up data 47
Ineffective 158 (65%)
Subsequent surgery 85
Died before surgery 15
No follow-up data 58
30-day mortality 61/756 (8%)
Complete success subgroup 45/558 (8%)
Failure subgroups with known follow-up 16/138 (12%)
Values are range, n (%), or n. *4 studies did not provide data for age. y5 studies did not provide data
for sex. z10 studies included a small number of patients with tricuspid OTPHV. x3 studies did not
provide information on location of OTPHV. k5 studies did not provide data for NYHA functional class.
{Failure includes 85 with partial success and 158 with no success.
CVA/emboli ¼ cerebrovascular accident (emboli/bleeding) and/emboli to other vascular sites.
NYHA ¼ New York Heart Association; OTPHV ¼ obstructive thrombosed prosthetic heart valve.
Table 2
Anticoagulation Status at Time of
Clinical Presentation
First Author (Ref. #) Adequate Inadequate
Aoyagi et al. (7) 14 6
Vitale et al. (8) 75 12
Manteiga et al. (9) 6 13
Gupta et al. (10) 62 48
Lengyel et al. (11) 70 15
Lopez et al. (12) 7 8
Teshima et al. (13) 16 11
Ramos et al. (14) 6 11
Roudaut et al. (15) 57 53
Renzulli et al. (17) 191 48
Caceres-Loriga et al. (20) 17 51
Ermis et al. (21) 10 23
Keuleers et al. (22) 16 15
Bollag et al. (24) 2 11
Ozkokeli et al. (25) 15 15
Lafci et al. (26) 5 13
Toker et al. (27) 35 28
Ahn et al. (28) 6 14
Total (n ¼ 1,005) 610 (61%) 395 (39%)
Values are n or n (%).
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and 65% presented in NYHA functional classes III/IV. Six
studies provided data regarding complete success according
to NYHA functional class on presentation (6,10,11,15,18,20)
(Table 4). Complete success was achieved in 81% of patients
presenting in NYHA functional classes I/II and 74% of
patients presenting in NYHA functional classes III/IV.
Streptokinase was used in 12 of the 17 studies. The recur-
rence rate was 13%. The rate of cerebrovascular accident
(CVA) or embolic phenomenon to other arterial sites was
14%. Some studies included tricuspid OTPHV; excluding
these, 481 involved the mitral PHV, and 151 involved the
aortic PHV.
The rate of complete success was 70%; we have labeled the
rest as failures of therapy. Of the failures, 85 (35%) had partial
success and 158 (65%) were ineffective with thrombolytic
agents. Of the partial successes, 1 patient died, 38 had surgery,
and follow-up was not provided in 47. Of the complete fail-
ures, 85 patients had surgery, 15 died before surgery could be
performed, and follow-up was not provided in 58.
The overall 30-day mortality was 8%. The 30-day mortality
in the complete success subgroup was 8% and in the failure
subgroup was 12%. However, follow-up data were not pre-
sented in 105 in the failure group.
LEFT-SIDED OTPHV TREATED WITH SURGERY AND PHV
RE-REPLACEMENT. Thirteen studies (7,11,16,17,21–29) pre-
sented baseline patient characteristics and clinical outcomes
in 662 patients with OTPHV who were treated surgically
(Online Table B); the ﬁndings are summarized in Table 5.
In 10 studies (8,12,17,18,22,23,25,28–30), of 543 patients,
490 (91%) had surgery as the initial therapy of OTPHV. In
other words, in these 10 studies, 9% of the patients hadsurgery following failure of thrombolytic therapy. The
majority of the patients were female (66%); the patients’ ages
ranged from 36 to 59 years. All patients had received
a mechanical PHV. Time from initial PHV implantation
to OTPHV ranged from 4 months to 14 years. Eighty-one
percent of patients with OTPHV were in NYHA functional
classes III/IV. Occurrence of CVA or emboli was 6%. The
initial success can be considered to be complete because the
obstructed valves were replaced and any remaining thrombus
was removed; 3 studies (17,22,29) had reported a recurrence.
In these 3 studies, of a pooled total of 367 patients, 21 (6%)
patients had a recurrence of OTPHV. Some studies in-
cluded tricuspid OTPHV; excluding these, of the 620 pa-
tients, 483 had mitral OTPHV, and 137 patients had aortic
OTPHV. The 30-day mortality was 15%.
Limitations of these data. There are a large number of
patients in the pooled data from the cited studies which is an
advantage. However:
1. The details of the patients both at baseline and on
follow-up that were included in the publications were
variable;
2. A total of 12 studies with left-sided OTPHV also
had an occasional patient with tricuspid OTPHV.
However, this was not a serious problem relating to
the analysis of this review because the data on isolated
Table 5
Summary of Pooled Data With Surgical Treatment for
Left Heart OTPHV
n 662
Mean age, yrs* 36–59
Sexy
Female 211 (66%)
Male 111 (34%)
Location of valvez
Mitral 483 (73%)
Aortic 137 (21%)
NYHA functional class
I/IIx 48 (19%)
III/IVx 199 (81%)
Initial therapy with surgery 490 (91%)
Surgery after failed thrombolysisk 53 (9%)
Complete success 662 (100%)
Recurrence{ 21 (6%)
CVA/emboli 37 (6%)
30-day mortality 98 (15%)
Values are n, range, or n (%). *Three studies did not provide data for age. y4 studies did not provide
data for sex. z6 studies included a small number of patients with tricuspid OTPHV. x4 studies did
not provide data for NYHA FC. jj3 studies did not provide data for preceding failed thrombolysis.
{3 studies provided data on recurrence.
Abbreviations as in Table 3.
Table 4
Patients Who Had Complete Success With Thrombolysis
for OTPHV Based on NYHA FC at Baseline
First Author (Ref. #)
NYHA
Functional Class I/II
NYHA
Functional Class III/IV
Patients CS Patients CS
Karthikeyan et al. (6) 82 61 37 9
Gupta et al. (10) 25 20 85 69
Lengyel et al. (11) 6 5 26 22
Roudaut et al. (15) 37 30 90 60
Tong et al. (18) 39 35 68 58
Caceres-Loriga et al. (20) 4 4 64 54
Total 193 156 (81%) 370 272 (74%)
Values are n or n (%).
CS ¼ complete success; NYHA ¼ New York Heart Association; OTPHV ¼ obstructive thrombosed
prosthetic heart valve.
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showed 88% of patients had complete success with
thrombolysis and had no serious complications. Thus,
the data on left-sided OTPHV appear valid for left-
sided OTPHV;
3. The studies on left-sided OTPHV included throm-
bosed aortic and mitral PHV. The stated number of
patients in each location of PHV tended to be very
small in several studies and outcomes in each location
of PHV had been frequently combined;
4. The reviewed studies mostly do not provide reasons
for the choice of thrombolysis or of surgery as initial
therapy; and
5. The outcomes of patients who had failure with
thrombolytic agents (partial success and ineffective)
are not completely described. The follow-up outcomes
in 105 episodes who remained in these 2 subgroups of
failures were not described. It is clinically likely that at
least some of them died, and the reported 30-day
mortality of 61 (8%) is most likely an underestimate
of the total mortality with thrombolytic agents.
Summary. Nevertheless, the data provided by the review in
the preceding text has provided important clinical infor-
mation that is valuable and are summarized as follows:
1. Fluoroscopy and 2-dimensional echocardiography
(TTE and TEE) were the main techniques that were
utilized. It is possible that in the future, 3-dimensional
echocardiography, computed tomography, and mag-
netic resonance imaging will document in multiple
studies the accuracy, especially for the diagnosis
and assessment of the extent of associated pannus
formation. Importantly, their relationship to clinical
outcome also has to be documented. Fluoroscopy
alone for the diagnosis and assessment of thrombus
and/or obstruction may be of limited value.
2. Thirty-nine percent of the patients had subthera-
peutic anticoagulation at the time of clinical pre-
sentation. These data should be interpreted with
caution. It is known that “rapid” changes in theintensity of anticoagulation status leads to thrombus
formation (30,31). Thus, the subtherapeutic and
therapeutic status at clinical presentation may not be
representative of anticoagulation status at the time of
start of thrombus formation, that is in the weeks/
months before the diagnosis of OTPHV.
3. Tricuspid OTPHV: thrombolytic therapy was suc-
cessful in 88% of the patients; surgery can be reserved
for those in whom thrombolysis is not adequate.
4. Left-sided OTPHV:
a. Fifty-nine percent to 66% of the episodes occurred
in women. All but 3 valves were mechanical valves.
The mitral valve was affected in about two-thirds
to three-fourths of the patients.
b. A comparatively small amount of thrombus at
the hinges of a mechanical valve can result in
OTPHV and be associated with severe symptoms.
One can postulate this accounts for rapid com-
plete success of thrombolytic agents in at least
some of the patients who were in NYHA func-
tional classes III/IV.
c. Of patients who were treated with thrombolytic
agents, 35% were in NYHA functional classes I/II.
Complete success was achieved in 81%. The inci-
dence of NYHA functional classes III/IV was 65%,
and complete success was achieved in 74%. The
incidence of CVA/emboli and of recurrence was
14% and 13%, respectively. Emboli may occur in
peripheral arteries and coronary arteries. Patients
with complete success of OTPHV had a mortality
of 8%. They may have died of complications such
as CVA (embolic/bleeding) and systemic and
Table 6 Suggested Therapeutic Strategies for OTPHV*
Right-sided OTPHV
Thrombolytic therapy is ﬁrst choice
Surgery if thrombolysis is unsuccessful
Left-sided OTPHV
Thrombolysis is ﬁrst choice for:
Patients in NYHA functional class I/II
Those with very severe comorbid conditions that would be associated with
a very high surgical operative mortality
If surgery is not a viable option
Patient refuses surgery
“Small thrombus” (area <0.8 cm2) with or without previous stroke
Surgery is ﬁrst choice for:
Prosthesis replacement that is necessary or appropriate
Those in whom the coronary blood ﬂow is potentially or actually compromised
Contraindications to thrombolytic therapy
Pannus is a signiﬁcant contributor to the obstruction
Surgery that may be needed urgently in those with unsuccessful thrombolysis
Surgery may be the preferred therapy initially for:
Patients in NYHA functional class III/IV
Large thrombus (area 0.8 cm2)
*For limitations of these strategies, see text.
Abbreviations as in Table 3.
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failure of thrombolytic agents was at least 12%.
d. Of patients who were treated with surgery, 81%
were in NYHA functional classes III/IV, and
complete success was achieved in all. The inci-
dences of CVA/emboli and of recurrence in
those who had surgery was 6% and 6%, res-
pectively. The mortality with surgery was 15%,
which may be partly related to a high incidence
(81%) of NYHA functional classes III/IV at
clinical presentation.
5. Because both therapies are associated with complica-
tions and mortality, routine initial thrombolytic
therapy followed by surgery can be considered to
constitute a form of “double jeopardy,” because
thrombolytic therapy might delay the initiation of
surgical therapy if it becomes necessary. In the series
we reviewed, 15 patients died while awaiting surgery
after failure of thrombolytic agents. Streptokinase was
used in 12 of the 17 studies of thrombolysis, and the
suggested time lag for performing surgery after using
streptokinase is 24 h after discontinuation of the
ﬁbrinolytic infusion or 2 h after ﬁbrinolytic activity has
been neutralized via protease inhibition, that is,
aprotinin (32). In addition, 15 patients died while
awaiting surgery after failure of thrombolytic agents.
Surgery in these clinical situations should be consid-
ered “emergent” or “urgent,” depending on the clinical
status of the patient. Also, the mortality in the failure
group is higher. These issues must be considered in
making the choice of initial therapy, which should also
be carefully explained to the patient before initiating
therapy.6. One study (18) indicated that use of thrombolytic
agents in those with thrombus size area 0.8 cm2 was
associated with a very high complication rate (41%)
and higher mortality (12.9%) in those in NYHA
functional classes III to IV. The method of measuring
thrombus area was not described. Additional studies
are needed. Rarely, thrombi can be very large and are
obviously not suitable for therapy with thrombolytic
agents (33).
Conclusions
For tricuspid valve OTPHV, thrombolytic therapy is the
optimal initial therapy. For left-sided OTPHV, thrombo-
lytic therapy is easier to administer than is surgery but is
associated with complication rates and of recurrence of 14%
and 13%, respectively. Complete success of thrombolysis is
achieved in 70% but is associated with serious complications
and a mortality of 8%. In the 30% who have failure of
thrombolytic therapy, surgery is necessary, frequently
urgently; their mortality is at least 12%, the outcome in this
subgroup may have been much worse, additional studies
with complete follow-up information are needed. Surgery is
associated with a higher mortality of 15%, but 81% of these
patients were in NYHA functional classes III/IV. It was
associated with lower complication and recurrence rates of
6%. Complete success of thrombosis can be assumed to be
100% because the thrombosed PHV and residual thrombus
were removed.
Suggested therapeutic strategies for OTPHV. We have
developed suggested strategies for treatment of OTPHV
(Table 6). The data related to the strategies were not
included or were not complete in the studies that were
included in our review. Therefore, the suggestions are partly
based on our detailed and critical analysis of the 27 studies
cited in this review, also on our clinical experience over many
decades and judgment, but they are partly difﬁcult to
quantitate at the present time.
LIMITATIONS OF SUGGESTED STRATEGIES.
1. Thrombus area data are based on 1 study (18).
Moreover, that study did not describe the method for
the measurement/calculation of thrombus area;
2. The “very high” surgical operative mortality is difﬁcult
to quantitate because: 1) it is partly related to surgical
experience at each medical center; and 2) OTPHV is
potentially a lethal disorder, and thus, even a very high
operative mortality, say 40% to 50%, may be consid-
ered appropriate in selected cases;
3. Surgery not being a viable option is difﬁcult to deﬁne,
but examples include patients in remote rural areas
and inadequately insured patients who may have
difﬁculty in accessing surgery 24 h, 7 days/week; and
4. Subvalvular pannus is an important factor that was
present in 59% of patients at surgery (Table 1). It
would be suspected of contributing to obstruction in
patients who underwent valve replacement in the
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with obstruction who have well-documented adequate
anticoagulation. Also, underlying pannus leading to
thrombotic obstruction may be preceded by gradual
increase in transprosthetic pressure gradients.
Strategy after successful thrombolysis. This information
was also not uniformly presented in the reviewed studies.
However, from the 1960s, patients have received adequate
anticoagulation with warfarin and more recently have had
additional clopidogrel or aspirin. They have been given
intravenous unfractionated heparin during the interim
period as a bridging procedure till therapeutic anti-
coagulation is achieved.
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